Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

New fibrate use and acute renal outcomes in elderly adults: a population-based study.

Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Moist L, Parikh CR, Paterson JM, Wald R, Yao Z, Garg AX.

Ann Intern Med. 2012 Apr 17;156(8):560-9. doi: 10.7326/0003-4819-156-8-201204170-00003.

PMID:
22508733
2.

Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V.

J Am Coll Cardiol. 2012 Nov 13;60(20):2061-71. doi: 10.1016/j.jacc.2012.07.049. Epub 2012 Oct 17. Review.

3.
4.

Cystatin C as a risk factor for outcomes in chronic kidney disease.

Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ.

Ann Intern Med. 2007 Jul 3;147(1):19-27.

PMID:
17606957
5.

Use of fibrates in the United States and Canada.

Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM.

JAMA. 2011 Mar 23;305(12):1217-24. doi: 10.1001/jama.2011.353.

6.

Impaired kidney allograft function following ezetimibe therapy.

Nouri-Majalan N, Moghaddasi S, Majidi R.

Iran J Kidney Dis. 2011 Mar;5(2):133-5.

7.

Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.

Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D.

Ann Intern Med. 2009 Nov 3;151(9):622-30. doi: 10.7326/0003-4819-151-9-200911030-00144. Review.

PMID:
19884623
8.

Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study.

Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Rehman F, Garg AX.

Ann Intern Med. 2014 Aug 19;161(4):242-8. doi: 10.7326/M13-2796.

9.

CKD and risk of hospitalization and death with pneumonia.

James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, Hemmelgarn BR; Alberta Kidney Disease Network.

Am J Kidney Dis. 2009 Jul;54(1):24-32. doi: 10.1053/j.ajkd.2009.04.005. Epub 2009 May 17.

PMID:
19447535
11.

Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials.

Sahebkar A, Simental-Mendía LE, Watts GF, Golledge J.

Atherosclerosis. 2015 May;240(1):284-96. doi: 10.1016/j.atherosclerosis.2015.03.016. Epub 2015 Mar 16. Review.

PMID:
25828270
12.

Risk of acute kidney injury from oral acyclovir: a population-based study.

Lam NN, Weir MA, Yao Z, Blake PG, Beyea MM, Gomes T, Gandhi S, Mamdani M, Wald R, Parikh CR, Hackam DG, Garg AX.

Am J Kidney Dis. 2013 May;61(5):723-9. doi: 10.1053/j.ajkd.2012.12.008. Epub 2013 Jan 10.

PMID:
23312723
13.

Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.

Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF; ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease).

Ann Intern Med. 2011 Mar 1;154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005.

PMID:
21357908
14.

Modification of outcomes after acute kidney injury by the presence of CKD.

Pannu N, James M, Hemmelgarn BR, Dong J, Tonelli M, Klarenbach S; Alberta Kidney Disease Network.

Am J Kidney Dis. 2011 Aug;58(2):206-13. doi: 10.1053/j.ajkd.2011.01.028. Epub 2011 Apr 15.

PMID:
21496979
15.

Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.

Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK.

Circ Heart Fail. 2011 Jan;4(1):18-26. doi: 10.1161/CIRCHEARTFAILURE.109.932558. Epub 2010 Oct 29.

17.

Renal and vascular protective effects of ezetimibe in chronic kidney disease.

Morita T, Morimoto S, Nakano C, Kubo R, Okuno Y, Seo M, Someya K, Nakahigashi M, Ueda H, Toyoda N, Kusabe M, Jo F, Takahashi N, Iwasaka T, Shiojima I.

Intern Med. 2014;53(4):307-14. Erratum in: Intern Med. 2015;54(13):1683.

18.

Fibrates and estimated glomerular filtration rate: observations from an outpatient clinic setting and clinical implications.

Abbas A, Saraf S, Ramachandran S, Raju J, Ramachandran S.

Postgrad Med J. 2012 Sep;88(1043):503-6. doi: 10.1136/postgradmedj-2011-130594. Epub 2012 Mar 29.

PMID:
22460858
19.

Safety considerations with fibrate therapy.

Davidson MH, Armani A, McKenney JM, Jacobson TA.

Am J Cardiol. 2007 Mar 19;99(6A):3C-18C. Epub 2006 Dec 8. Review.

PMID:
17368275
20.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

Items per page

Supplemental Content

Write to the Help Desk